Avastin approval surprises Wall Street; may change future of cancer drug approvals

Share this article:
Friday's approval of Genentech's Avastin to treat breast cancer caught many on Wall Street off guard and could represent a change in the way the agency measures the effectiveness of cancer medicines. 

Going against the advice of its advisory panel, the agency based its decision on measurements of tumor growth in patients using Avastin, not patient survival.

Wall Street analysts had widely expected the agency to delay its decision and review new data submitted from a study sponsored by Roche, which holds a majority stake in Genentech and sells Avastin outside the US.

“The news comes as a surprise, since the FDA's Oncologics Drug Advisory Committee in December voted five to four against approval for the drug,” wrote Friedman, Billings, Ramsey & Co. (FBR) analyst Jim Reddoch in a research note issued on Feb. 25.

FDA approval for drugs targeted at cancer patients who have never been treated before usually depends upon data showing that a drug extended, or improved the quality of, patients' lives. Avastin showed neither in a study submitted by Genentech, though the drug did slow tumor growth. Analysts on Wall Street believe the Avastin decision could open the door for more cancer drugs to be approved based on their tumor-shrinking ability.

Avastin is already approved to treat colon and lung cancer and is considered Genentech's most important drug by Wall Street.

In 2007, the drug had US sales of $2.3 billion. One analyst estimated its use for breast cancer treatment could add nearly $500 million a year.

“We are raising our US Avastin sales estimates in breast cancer, beginning this year out to 2012,” FBR's Reddoch said. “Our 2008 Avastin estimate is $2.6 billion. By 2012, we are forecasting nearly $860 million in U.S. breast cancer sales, translating into a 39% penetration of the market, up from Avastin's current 25% penetration. We are raising our price target to $76 from $67.” FBR will maintain its market perform rating, Reddoch said.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...